← 返回

高剂量抗坏血酸在体外和体内模型中与抗 PD1 治疗在非小细胞肺癌中协同作用

英文原题:High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer in vitro and in vivo models.

查看英文原题

High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer in vitro and in vivo models.

PubMed 2025/01/17(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们的结果表明,高剂量 AA 可能是增强抗 PD1 免疫疗法疗效的一种有前景的佐剂。

研究思路结论见上方概要

靶向程序性细胞死亡蛋白1(PD1)的免疫检查点抑制剂(ICIs)为非小细胞肺癌(NSCLC)患者带来了显著的生存获益。然而,仍存在巨大的未满足需求,即确定克服耐药并为这些患者带来获益的治疗方法。高剂量抗坏血酸(AA)与许多标准抗癌治疗具有协同作用。然而,关于高剂量AA在提高NSCLC中抗PD1抑制剂疗效方面的作用知之甚少。本研究旨在阐明高剂量AA在NSCLC抗PD1免疫治疗中的效果。

采用H460细胞与CD8+ T细胞的共培养模型及LLC1肺癌同源小鼠模型,研究了大剂量AA与anti-PD1的联合效应。为探究其分子机制,利用nano-LC-ESI-MS/MS对小鼠肿瘤组织进行了全面蛋白质组学分析。

高剂量AA预处理增强了健康供者来源的CD8+ T细胞对H460细胞的细胞毒性敏感性。此外,抗PD1与高剂量AA联合显著增加了H460细胞中CD8+ T细胞的细胞毒性。抗PD1与高剂量AA联合在肺癌同系小鼠模型中显示出显著的抗肿瘤效果,显著减少了肿瘤生长,并增加了CD8+ T细胞依赖性细胞毒性和巨噬细胞活性。综合蛋白质分析证实,在抗PD1治疗的肿瘤组织中,高剂量AA通过调节多种免疫相关机制增强了抗肿瘤效果,包括B细胞和T细胞受体信号通路、Fc gamma R介导的吞噬作用以及自然杀伤(NK)细胞介导的细胞毒性。

展开英文摘要原文

The combined effects of high-dose AA and anti-PD1 were investigated using a coculture model of H460 cells and CD8+ T cells and an LLC1 lung cancer syngeneic mouse model. To investigate the molecular mechanism, tumor tissues from mice were analyzed by comprehensive proteomic profiling using nano-LC-ESI-MS/MS.

Pretreatment with a high dose of AA led to enhanced the sensitivity to the cytotoxicity of CD8+ T cells derived from healthy donor for H460 cells. Additionally, the combination of anti-PD1 and high-dose AA significantly increased CD8+ T cell cytotoxicity in H460 cells. The combination of anti-PD1 and high-dose AA showed dramatic antitumor effects in a syngeneic mouse model of lung cancer by significantly reducing tumor growth and increasing CD8+ T cell-dependent cytotoxicity and macrophage activity. Comprehensive protein analysis confirmed that high-dose AA in anti-PD1-treated tumor tissues enhanced the antitumor effects by regulating various immune-related mechanisms, including the B cell and T cell receptor signaling pathways, Fc gamma R-mediated phagocytosis, and natural killer (NK) cell-mediated cytotoxicity. DISCUSSION: Our results suggest that high-dose AA may be a promising adjuvant to potentiate the efficacy of anti-PD1 immunotherapy.

论文信息

作者
Kim HS、Kwon SH、Choi OK、Lim T
单位
Veterans Medical Research Institute, Veterans Health Service Medical Center, Seoul, Republic of Korea.South Korea
文献类型
非美国政府资助研究
期刊
Frontiers in immunology2024
原文标识
PubMed 39896806 · DOI 10.3389/fimmu.2024.1512605